|Focusing on the preventability of adverse drug reactions.|
GT Schumock, JP Thornton
Hospital pharmacy 27 (6), 538-538, 1992
|Pure red-cell aplasia and epoetin therapy|
CL Bennett, S Luminari, AR Nissenson, MS Tallman, SA Klinge, ...
New England Journal of Medicine 351 (14), 1403-1408, 2004
|Evidence of the economic benefit of clinical pharmacy services: 1996–2000|
GT Schumock, MG Butler, PD Meek, LC Vermeulen, BV Arondekar, ...
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 23 (1 …, 2003
|Economic evaluations of clinical pharmacy services—1988–1995|
Publications Committee of the American College of Clinical Pharmacy, ...
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 16 (6 …, 1996
|Economic considerations in Alzheimer's disease|
PD Meek, EK McKeithan, GT Schumock
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 18 (2P2 …, 1998
|Economic evaluations of clinical pharmacy services: 2001–2005|
F Doloresco, JM Hoffman, PD Meek
Pharmacotherapy 28 (11), 285e-323e, 2008
|The financial burden of cancer: estimates from a study of insured women with breast cancer|
AM Arozullah, EA Calhoun, M Wolf, DK Finley, KA Fitzner, EA Heckinger, ...
J Support Oncol 2 (3), 271-278, 2004
|The research on adverse drug events and reports (RADAR) project|
CL Bennett, JR Nebeker, EA Lyons, MH Samore, MD Feldman, JM McKoy, ...
Jama 293 (17), 2131-2140, 2005
|Factors that influence prescribing decisions|
GT Schumock, SM Walton, HY Park, EA Nutescu, JC Blackburn, JM Finley, ...
Annals of Pharmacotherapy 38 (4), 557-562, 2004
|The incident user design in comparative effectiveness research|
ES Johnson, BA Bartman, BA Briesacher, NS Fleming, T Gerhard, ...
Pharmacoepidemiology and drug safety 22 (1), 1-6, 2013
|Exploring the use of social network methods in designing healthcare quality improvement teams|
D Meltzer, J Chung, P Khalili, E Marlow, V Arora, G Schumock, R Burt
Social science & medicine 71 (6), 1119-1130, 2010
|Prioritizing future research on off‐label prescribing: results of a quantitative evaluation|
SM Walton, GT Schumock, KV Lee, GC Alexander, D Meltzer, RS Stafford
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 28 (12 …, 2008
|National trends in prescription drug expenditures and projections for 2016|
GT Schumock, EC Li, KJ Suda, MD Wiest, JA Stubbings, LM Matusiak, ...
American Journal of Health-System Pharmacy 73 (14), 1058-1075, 2016
|The validity of International Classification of Diseases, Ninth Revision, Clinical Modification diagnosis codes for identifying patients hospitalized for COPD exacerbations|
BD Stein, A Bautista, GT Schumock, TA Lee, JT Charbeneau, ...
Chest 141 (1), 87-93, 2012
|Clopidogrel‐associated bleeding and related complications in patients undergoing coronary artery bypass grafting|
AS Pickard, RC Becker, GT Schumock, CB Frye
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 28 (3 …, 2008
|Thalidomide-associated deep vein thrombosis and pulmonary embolism|
CL Bennett, GT Schumock, AA Desai, HC Kwaan, DW Raisch, R Newlin, ...
The American journal of medicine 113 (7), 603-606, 2002
|Guidelines for acute decompensated heart failure treatment|
RJ DiDomenico, HY Park, MR Southworth, HM Eyrich, RK Lewis, ...
Annals of Pharmacotherapy 38 (4), 649-660, 2004
|Impact of Parkinson’s disease and its pharmacologic treatment on quality of life and economic outcomes|
RT Scheife, GT Schumock, A Burstein, MD Gottwald, MS Luer
American Journal of Health-System Pharmacy 57 (10), 953-962, 2000
|Characteristics associated with ability to prevent adverse drug reactions in hospitalized patients|
JD Seeger, SX Kong, GT Schumock
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 18 (6 …, 1998
|Dissemination of information on potentially fatal adverse drug reactions for cancer drugs from 2000 to 2002: first results from the research on adverse drug events and reports …|
LA Ladewski, SM Belknap, JR Nebeker, O Sartor, EA Lyons, TC Kuzel, ...
Journal of clinical oncology 21 (20), 3859-3866, 2003